Randomized Clinical Trial of Thrice-Weekly 4-Month Moxifloxacin or Gatifloxacin Containing Regimens in the Treatment of New Sputum Positive Pulmonary Tuberculosis Patients

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Jawahar, Mohideen S ^a   Banurekha, Vaithilingam V ^a   Paramasivan, Chinnampedu N ^a   Rahman, Fathima ^a   Ramachandran, Rajeswari ^a   Venkatesan, Perumal ^a   Balasubramanian, Rani ^a   Selvakumar, Nagamiah ^a   Ponnuraja, Chinnaiyan ^a   Iliayas, Allaudeen S ^b   Gangadevi, Navaneethapandian P ^b   Raman, Balambal ^a   Baskaran, Dhanaraj ^a   Kumar, Santhanakrishnan R ^b   Kumar, Marimuthu M ^b   Mohan, Victor ^b   Ganapathy, Sudha ^a   Kumar, Vanaja ^a   Shanmugam, Geetha ^a   Charles, Niruparani ^a   Sakthivel, Murugesan R ^b   Jagannath, Kannivelu ^c   Chandrasekar, Chockalingam ^d   Parthasarathy, Ramavaram T ^e   Narayanan, Paranji R ^a   more..

^a NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

^b National Institute for Research in Tuberculosis   (India)

^c Institute of Thoracic Medicine   (India)

^d Government Rajaji Hospital   (India)

^e Government Tiruvatteeswarar Hospital   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN;

ABDOMINAL DISCOMFORT; ADULT; ANTIBIOTIC SENSITIVITY; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DRUG ERUPTION; DRUG RESPONSE; DYSGLYCEMIA; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HUMAN; INDIA; LIVER DISEASE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; PERIPHERAL NEUROPATHY; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RECURRENT INFECTION; SEIZURE; SINGLE DRUG DOSE; SPUTUM CULTURE; VOMITING;

ADULT; ANTITUBERCULAR AGENTS; AZA COMPOUNDS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MIDDLE AGED; QUINOLINES; RECURRENCE; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84879743029     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067030     Document Type: Article

References (26)

1. Fox W, Ellard GA, Mitchison DA, (1999) Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 3: S231-S279.
2. Tuberculosis Research Centre (2002) Shortening short course chemotherapy: a randomised clinical trial for treatment of smear-positive pulmonary tuberculosis with regimens using ofloxacin in the intensive phase. Ind J Tuberc 49: 27-38.
3. Sirgel FA, Donald PR, Odhiambo J, Githui W, Umapathy KC, et al. (2000) A multicentre study of the early bactericidal activity of anti- tuberculosis drugs. J Antimicrob Chemother 45: 859-870.
4. Lounis N, Bentoucha A, Truffot-Pernot C, Ji B, O'Brien RJ, et al. (2001) Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 45: 3482-3486.
5. Hu Y, Coates AR, Mitchison DA, (2003) Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 47: 653-657.
6. Sulochana S, Rahman F, Paramasivan CN, (2005) In Vitro Activity of Fluoroquinolones against. Mycobacterium tuberculosis. Journal of Chemotherapy 17: 169-173.
7. Kubendiran G, Paramasivan CN, Sulochana S, Mitchison DA, (2006) Moxifloxacin and gatifloxacin in an acid model of persistent Mycobacterium tuberculosis. Journal of Chemotherapy 18: 617-623.
8. Stass H, Dalhoff A, Kubitza D, Schuhly U, (1998) Pharmacokinetics, safety and tolerability of ascending single doses of moxifloxacin, a new 8- methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother 42: 2060-2065.
9. Lober S, Ziege S, Rau M, Schreiber G, Mignot A, et al. (1999) Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium. Antimicrob Agents Chemother 43: 1067-1071.
10. Hong Kong Chest Service/British Medical Research Council (1977) Controlled trial of 6-month and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong. The results up to 30 months. Am Rev Respir Dis 115: 727-735.
11. Hong Kong Chest Service/British Medical Research Council (1982) Controlled trial of 4 three-times weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Second report: The results up to 24 months. Tubercle 63: 89-98.
12. Holst E, Mitchison DA, Radhakrishna S, (1959) Examination of smears for tubercle bacilli by fluorescence microscopy. Indian J Med Res 47: 495-499.
13. Petroff SA, (1915) A new and rapid method for the isolation and cultivation of tubercle bacilli directly from sputum and faeces. J Exp Med 21: 38-42.
14. Allen B, Baker FJ (1968) In Mycobacteria: Isolation, identification and sensitivity testing, London, Butterworths, 17.
15. Kubica SP, (1973) Differential identification of mycobacteria. VII: Key features for identification of clinically significant mycobacteria. Am Rev Respir Dis 107: 9-21.
16. Canetti G, Fox W, Khomenko A, Mahler HT, Menon NK, et al. (1969) Advances in techniques of testing mycobacterial drug sensitivity and the use of the sensitivity tests in tuberculosis control programs. Bull WHO 41: 21-43.
17. Subbammal S, Nair NGK, Radhakrishna S, Tripathy SP, (1978) Comparison of various measures of sensitivity of Mycobacterium tuberculosis to ethambutol. Tubercle 59: 185-191.
18. Sulochana S, Venkataraman P, Paramasivan CN, (1999) Evaluation of various methods of susceptibility to ofloxacin in strains of Mycobacterium tuberculosis. Indian J Med Res 110: 186-189.
19. Tuberculosis Research Centre, Madras (1983) Study of chemotherapy regimens of 5 and 7 months duration and the role of corticosteroids in the treatment of sputum positive patients with pulmonary tuberculosis in South India. Tubercle 64: 73-91.
20. Mathew R, Santha T, Parthasarathy R, Rajaram K, Paramasivan CN, et al. (1993) Response of patients with initially drug resistant organisms to treatment with short-course chemotherapy. Indian J Tuberc 40: 119-123.
21. Tuberculosis Research Centre, Chennai (1997) A controlled clinical trial of oral short course regimens in the treatment of sputum-positive pulmonary tuberculosis. Int J Tuberc Lung Dis 1: 509-517.
22. Dickinson JM, Mitchison DA (1968) In vitro and in vivo studies to assess the suitability of antituberculous drugs for use in intermittent chemotherapy regimens. Tubercle Suppl. 49: 66-70.
23. Chan CY, Yeang CA, Yew WW, Leung CC, Cheng AFB, (2004) In Vitro Postantibiotic Effects of Rifapentine, Isoniazid, and Moxifloxacin against Mycobacterium tuberculosis. Antimicrobial agents chemother 8: 340-343.
24. Greenberg AL Decerbo M, Fan J, (2005) Gatifloxacin Therapy Associated with Hypoglycemia. Clin Infect Dis 40: 1210-1211.
25. Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis (REMoxTB) NCT00864383. Available: http://clinicaltrials.gov/ct2/show/NCT00864383?term=moxifloxacininthetreatmentoftuberculosis&rank=3. Accessed 2013 May 22.
26. A Controlled Trial of a 4-Month Quinolone-Containing Regimen for the Treatment of Pulmonary Tuberculosis. NCT00216385. Available: http://clinicaltrials.gov/ct2/show/NCT00216385?term=gatifloxacininthetreatmentoftuberculosis&rank=1. Accessed 2013 May 22.